Bibliography
- Jetten AM, Joo JH. Retinoid-related orphan receptors (RORs): roles in cellular differentiation and development. Adv Dev Biol 2006;16:313-55
- Burris TP, Busby SA, Griffin PR. Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 2012;19(1):51-9
- Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009;7:e003
- Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11(10):763-76
- Fauber BP, Magnuson S. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc). J Med Chem 2014;57(14):5871-92
- Zhang Y, Luo X, Wu D, Yong X. ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin 2015;36(1):71-87
- Sun H, Tawa G, Wallqvist A. Classification of scaffold hopping approaches. Drug Discov Today 2012;17(7-8):310-24
- Glaxo Group Ltd. Compounds useful as retinoid-related orphan receptor gamma modulators. WO2012100734; 2012
- Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as RORgammaT modulator. WO2013171729; 2013
- Wang Y, Cai W, Zhang G, et al. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors. Bioorg Med Chem 2014;22(2):692-702
- Gege C, Schlüter T, Hoffmann T. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt. Bioorg Med Chem Lett 2014;24(22):5265-7
- Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds of ROR gamma modulators. WO2015008234; 2015
- Merck Sharp & Dohme Corp. RORgammaT inhibitors. WO2012106995; 2012
- Wang Y, Kumar N, Crumbley C, et al. A second class of nuclear receptors for oxysterols: regulation of RORα and RORγ activity by 24S-hydroxycholesterol (cerebrosterol). Biochim Biophys Acta 2010;1801(8):917-23
- Soroosha P, Wua J, Xuea X, et al. Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Proc Natl Acad Sci USA 2014;111(33):12163-8
- Hu X, Wang Y, Hao L-Y, et al. Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonists. Nat Chem Biol 2015;11(2):141-7
- Santori FR, Huang P, van de Pavert SA, et al. Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab 2015;21(2):286-97
- Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2011;2:349-55
- Fauber BP, René O, de Leon Boenig G, et al. Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. Bioorg Med Chem Lett 2014;24(16):3891-7
- The clogD was calculated using standard settings with MarvinView from ChemAxon Ltd
- Kumar N, Solt LA, Conkright JJ, et al. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-α/γ inverse agonist. Mol Pharmacol 2010;77(2):228-36
- Giordanetto F, Boström J, Tyrchan C. Follow-on drugs: how far should chemists look? Drug Discov Today 2011;16(15-16):722-32
- Tostmann H. Protecting chemistry inventions: the double-edged sword of being an unpredictable art. ACS Med Chem Lett 2015;6(4):364-6
- Merck Sharp & Dohme Corp. 4-Heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof. WO2014028589; 2014
- Merck Sharp & Dohme Corp. N-Alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof. WO2014028591; 2014
- Merck Sharp & Dohme Corp. 3-Cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof. WO2014028597; 2014
- Merck Sharp & Dohme Corp. 3-Aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof. WO2014028600; 2014
- F. Hoffmann-La Roche AG/Genentech Inc. Keto-imidazopyridine derivatives as RORc modulators. WO2015036411; 2015
- Fauber BP, Gobbi A, Robarge K, et al. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. Bioorg Med Chem Lett 2015;25(15):2907-12